Ophthalmology

Los Angeles Eye Group Pioneers Non-Surgical JETREA Treatment for Vitreomacular Adhesion

After the FDA approved the use of JETREA injections to treat vitreomacular adhesion last October, Los Angeles-based Retina-Vitreous Associates Medical Group claims it is the first on the West Coast to use the drug to treat VMA patients non-surgically.

Jim McLaughlin

Tuesday, February 5th, 2013

JETREA (ocriplasmin) is a proteolytic enzyme that is injected into the eye in a single dose to break down proteins that adhere the vitreous to the macula.

Next Up in Ophthalmology

Maryland ophthalmology practices merge, open joint facility

Maryland Vision Institute and Busack Eye Center have opened a shared practice in Frederick, Md. The two practices will begin…

By: Cameron Cortigiano
Friday, January 9th, 2026
3 Oklahoma ophthalmology practices acquired

Orlando, Fla.-based Ascend Vision Partners entered the Oklahoma market with the acquisition of three practices. according to a Jan. 7…

By: Patsy Newitt
Thursday, January 8th, 2026
VisionPoint Eye Center settles data breach lawsuit for $750K

Bloomington, Ill.-based VisionPoint Eye Center has agreed to pay $750,000 to settle a class-action lawsuit related to a 2024 data…

By: Cameron Cortigiano
Monday, December 29th, 2025

Comments are closed.

More Articles on Ophthalmology:

Why DSOs are rethinking automation in 2026

Next Up in Ophthalmology

Maryland ophthalmology practices merge, open joint facility

3 Oklahoma ophthalmology practices acquired

VisionPoint Eye Center settles data breach lawsuit for $750K

Join the 40,000+ ASC leaders who start their day with Becker's